AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve analysts that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $41.45.

Several equities analysts recently commented on ANAB shares. JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a research report on Thursday, December 19th. Truist Financial decreased their price target on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a report on Wednesday, December 18th. Wedbush reissued an "outperform" rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Wells Fargo & Company reduced their target price on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday, December 12th. Finally, Guggenheim dropped their price target on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th.

AnaptysBio Price Performance

NASDAQ ANAB traded up $0.70 on Monday, hitting $15.30. The stock had a trading volume of 874,254 shares, compared to its average volume of 784,418. The business's fifty day moving average price is $19.75 and its 200 day moving average price is $28.51. The stock has a market cap of $465.56 million, a price-to-earnings ratio of -2.52 and a beta of -0.02. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts anticipate that AnaptysBio will post -6.02 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 65,184 shares of the business's stock in a transaction dated Monday, December 30th. The stock was purchased at an average cost of $12.92 per share, with a total value of $842,177.28. Following the acquisition, the director now directly owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

Institutional Trading of AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in ANAB. JPMorgan Chase & Co. grew its holdings in AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after purchasing an additional 22,164 shares during the period. Barclays PLC lifted its position in shares of AnaptysBio by 117.4% during the 3rd quarter. Barclays PLC now owns 44,300 shares of the biotechnology company's stock valued at $1,486,000 after buying an additional 23,926 shares in the last quarter. Geode Capital Management LLC grew its stake in AnaptysBio by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock valued at $15,594,000 after acquiring an additional 13,336 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock worth $74,008,000 after acquiring an additional 43,598 shares in the last quarter. Finally, XTX Topco Ltd raised its position in AnaptysBio by 49.1% during the third quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company's stock worth $680,000 after acquiring an additional 6,683 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.